Epithelial Ovarian Cancer

Dewhurst's Textbook of Obstetrics & Gynaecology, Seventh Edition

Volumn , Issue , 2008, Pages 625-635

  Gabra, Hani ^a,b,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Ovarian Cancer Action Research Unit   (United Kingdom)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Cell carcinomas; Endometriosis; Epithelial ovarian cancer; Lymphadenectomy; Prophylactic oophorectomy

Indexed keywords

EID: 84891338558     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470753354.ch55     Document Type: Chapter

References (54)

1. Boyle P & Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16(3), 481-8.
2. Parkin DM, et al. (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2), 74-108.
3. Fathalla MF (1971) Incessant ovulation-a factor in ovarian neoplasia? Lancet 2(7716), 163.
4. Greer JB, et al. (2005) Short-term oral contraceptive use and the risk of epithelial ovarian cancer. Am J Epidemiol 162(1), 66-72.
5. Ness RB & Cottreau C (1999) Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91(17), 1459-67.
6. Ness RB (2003) Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol 189(1), 280-94.
7. Herrinton LJ, et al. (1994) Ovarian cancer incidence among Asian migrants to the United States and their descendants. J Natl Cancer Inst 86(17), 1336-9.
8. Sogaard M, Kjaer SK & Gayther S (2006) Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention. Acta Obstet Gynecol Scand 85(1), 93-105.
9. Baldwin RL, et al. (2000) BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 60(19), 5329-33.
10. Hall J, Paul J & Brown R (2004) Critical evaluation of p53 as a prognostic marker in ovarian cancer. Expert Rev Mol Med 2004, 1-20.
11. Dinulescu DM, et al. (2005) Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11(1), 63-70.
12. Sherbet GV & Patil D (2003) Genetic abnormalities of cell proliferation, invasion and metastasis, with special reference to gynaecological cancers. Anticancer Res 23(2B), 1357-71.
13. Sharma A & Menon U (2006) Screening for gynaecological cancers. Eur J Surg Oncol.
14. Kauff ND, et al. (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346(21), 1609-15.
15. Ransohoff DF (2005) Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst 97(4), 315-9.
16. Goff BA, et al. (2004) Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. Jama 291(22), 2705-12.
17. Leitao MM Jr., et al. (2004) Clinicopathologic analysis of early-stage sporadic ovarian carcinoma. Am J Surg Pathol 28(2), 147-59.
18. Kurman RJ & Trimble CL (1993) The behavior of serous tumors of low malignant potential: are they ever malignant? Int J Gynecol Pathol 12(2), 120-7.
19. Kaern J, et al. (1993) DNAploidy; the most important prognostic factor in patients with borderline tumors of the ovary. Int J Gynecol Cancer 3(6), 349-358.
20. Fox H & Buckley CH (1992) The female genital tract and ovaries., in Oxford Textbook of Pathology, N.A. Wright, Editor. Oxford University Press.: Oxford. 1563-1640.
21. Sugiyama T, et al. (2000) Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88(11), 2584-9.
22. Hess V, et al. (2004) Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 22(6), 1040-4.
23. Clark TG, et al. (2001) A prognostic model for ovarian cancer. Br J Cancer 85(7), 944-52.
24. Eisenhauer EA, Vermorken JB & van Glabbeke M (1997) Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]. Ann Oncol 8(10), 963-8.
25. Vasey PA (2003) Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br J Cancer 89 Suppl 3, S23-8.
26. Junor EJ, et al. (1999) Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol 106(11), 1130-6.
27. Griffiths CT & Fuller AF (1978) Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Surg Clin North Am 58(1), 131-42.
28. van der Burg ME, et al. (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332(10), 629-34.
29. Crawford SC, et al. (2005) Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol 23(34), 8802-11.
30. Trimbos JB, et al. (2003) International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 95(2), 105-12.
31. van der Burg ME & Vergote I (2003) The role of interval debulking surgery in ovarian cancer. Curr Oncol Rep 5(6), 473-81.
32. McGuire WP, et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334(1), 1-6.
33. Piccart MJ, et al. (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92(9), 699-708.
34. du Bois A, et al. (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17), 1320-9.
35. Enomoto T, et al. (2003) Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? in Proc Am Soc Clin Oncol.
36. Sandercock J, Parmar MK & Torri V (1998) First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence. Br J Cancer 78(11), 1471-8.
37. Muggia FM, et al. (2000) Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 18(1), 106-15.
38. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet, 2002. 360(9332), 505-15.
39. Guidance on the use of paclitaxel in the treatment of ovarian cancer., in Technology Appraisal No. 55, Issue date: January 2003 Review date: July 2003.
40. Bertelsen K, et al. (1993) A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol 49(1), 30-6.
41. Lambert HE, et al. (1997) A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Ann Oncol 8(4), 327-33.
42. Hakes TB, et al. (1992) Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 45(3), 284-9.
43. Muggia FM (2004) Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer. Semin Oncol 31(6 Suppl 15), 19-24.
44. Cure H, et al. (2004) Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/FNCLCC/SFGM-TC study. in ASCO Annual Meeting 2004: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition).
45. Ledermann JA, et al. (2005) A phase III randomised trial of sequential high dose chemotherapy (HDC) with peripheral blood stem cell support or standard dose Chemotherapy (SDC) for first-line treatment of ovarian cancer. in ASCO Annual Meeting. 2005: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings.
46. Armstrong DK, et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354(1), 34-43.
47. Hamilton CA, Berek JS (2006) Intraperitoneal chemotherapy for ovarian cancer. Curr Opin Oncol 18(5), 507-15.
48. Markman M & Walker JL (2006) Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol 24(6), 988-94.
49. Blackledge G, et al. (1989) Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 59(4), 650-3.
50. Parmar MK, et al. (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361(9375), 2099-106.
51. Gordon AN, et al. (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19(14), 3312-22.
52. Meyer T, et al. (2001) Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer. Ann Oncol 12(12), 1705-9.
53. de Jongh FE, et al. (2002) Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. Eur J Cancer 38(15), 2005-13.
54. Pfisterer J, et al. (2005) The role of surgery in recurrent ovarian cancer. Int J Gynecol Cancer 15 Suppl 3, 195-8.